학술논문
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.
Document Type
Article
Author
Source
Journal of Medicinal Chemistry; 4/14/2022, Vol. 65 Issue 7, p5317-5333, 17p
Subject
Language
ISSN
00222623